NASDAQ: ERNAErnexa Therapeutics Revenue
Ernexa Therapeutics revenue was $535.00k for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Mar 31, 2025 was $0.0, down 100% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ERNA annual revenue was $582.0k, with 755.9% growth year-over-year.
ERNA past revenue growth
How has ERNA's revenue growth performed historically?
Company
365.22%
Industry
1,675.38%
Market
37.92%
ERNA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ERNA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ERNA's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
ERNA revenue history
Current Revenue
$535.0k
Current Earnings
-$46.1M
Current Profit Margin
-8,618.7%
Be the first to know when ERNA announces revenue.
ERNA Revenue History By Year
| ERNA Yearly Revenue | ERNA Revenue | ERNA Change | ERNA Revenue Growth |
|---|---|---|---|
| 2024-12-31 | $582.00k | $514.00k | +755.88% |
| 2023-12-31 | $68.00k | N/A | N/A |
| 2022-12-31 | $0.00 | N/A | N/A |
| 2021-12-31 | $0.00 | N/A | N/A |
| 2020-12-31 | $0.00 | -$19.81M | -100.00% |
| 2019-12-31 | $19.81M | -$3.53M | -15.12% |
| 2018-12-31 | $23.34M | $2.06M | +9.69% |
| 2017-12-31 | $21.27M | -$1.04M | -4.65% |
| 2016-12-31 | $22.31M | -$2.21M | -9.00% |
| 2015-12-31 | $24.52M | -$1.53M | -5.86% |
| 2014-12-31 | $26.05M | $2.30M | +9.67% |
| 2013-12-31 | $23.75M | -$315.00k | -1.31% |
| 2012-12-31 | $24.06M | $194.00k | +0.81% |
| 2011-12-31 | $23.87M | -$1.44M | -5.69% |
| 2010-12-31 | $25.31M | -$505.00k | -1.96% |
| 2009-12-31 | $25.81M | -$1.68M | -6.12% |
| 2008-12-31 | $27.50M | -$3.05M | -9.97% |
| 2007-12-31 | $30.54M | -$2.44M | -7.41% |
| 2006-12-31 | $32.99M | $2.24M | +7.27% |
| 2005-12-31 | $30.75M | $4.47M | +16.99% |
| 2004-12-31 | $26.28M | -$3.21M | -10.87% |
| 2003-12-31 | $29.49M | $3.88M | +15.15% |
| 2002-12-31 | $25.61M | $3.05M | +13.52% |
| 2001-12-31 | $22.56M | $511.00k | +2.32% |
| 2000-12-31 | $22.05M | -$1.70M | -7.16% |
| 1999-12-31 | $23.75M | -$446.00k | -1.84% |
| 1998-12-31 | $24.19M | -$1.67M | -6.45% |
| 1997-12-31 | $25.86M | $150.00k | +0.58% |
| 1996-12-31 | $25.71M | $5.63M | +28.03% |
| 1995-12-31 | $20.08M | $3.94M | +24.38% |
| 1994-12-31 | $16.15M | -$1.11M | -6.44% |
| 1993-12-31 | $17.26M | N/A | N/A |
Ernexa Therapeutics Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.